ODAC Briefing for NM-CRPC

First Page		Document Content
Prostate-specific antigen Bone metastasis MCRPC Management of prostate cancer William K. Oh Medicine Prostate cancer Metastasis		ODAC Briefing for NM-CRPC Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 138,50 KB Share Document on Facebook

	Intranet “Internal News” Posting & Leading Edge article, authored by Kathy, Dede or Rob DocID: 188GI - View Document
	BioMed Research International Special Issue on Optimal Sequencing and/or Combination of the New Drugs for mCRPC CALL FOR PAPERS DocID: 14mJD - View Document
	«ETTORE MAJORANA» FOUNDATION AND CENTRE FOR SCIENTIFIC CULTURE TO PAY A PERMANENT TRIBUTE TO GALILEO GALILEI, FOUNDER OF MODERN SCIENCE AND TO ENRICO FERMI, THE “ITALIAN NAVIGATOR”, FATHER OF THE WEAK FORCES INTERN DocID: 12TGh - View Document
	6.1 ABIRATERONE ACETATE, tablet, 250 mg, Zytiga®, Janssen-Cilag Pty Ltd Purpose of Application Authority required listing for abiraterone for treatment of metastatic castrate-resistant prostate cancer (mCRPC) after tre DocID: YQgm - View Document
	Daniel P. Petrylak, M.D. CURRICULUM VITAE Date of Revision: February 7, 2014 Name: DocID: QDQi - View Document